Hemostemix Expands With First Cardiology Practice Acquisitions
CALGARY, Alberta — November 26, 2025. Hemostemix Inc. has taken a major step in its global clinical-commercial expansion, announcing...
AI drug discovery Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
CALGARY, Alberta — November 26, 2025. Hemostemix Inc. has taken a major step in its global clinical-commercial expansion, announcing...
Toronto, Canada – October 22, 2025 — Visionary Holdings Inc., a global education and technology enterprise, announced the launch...
CALGARY, Alberta, Oct. 9, 2025 — Hemostemix has filed for Institutional Review Board (IRB) approval of its Phase 1...
San Diego, CA – September 23, 2025 — Gallant, an animal-health biotechnology company specializing in regenerative medicine, announced that...
